MarketCap
Facebook
X
Telegram
LogicBio Therapeutics DSO Ratio | LOGC
Annual DSO Ratio LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.88 | 13.9 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.9 | 9.88 | 11.9 |
Quarterly DSO Ratio LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.01 | 0.86 | 0.97 | - | 4.22 | 9.44 | 34.8 | - | 25.9 | 24.9 | 11.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.8 | 0.86 | 12.7 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
7.42 | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
111 | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
3.58 | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |
 |
Akebia Therapeutics
AKBA
|
62.9 | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alkermes plc
ALKS
|
88.9 | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Alnylam Pharmaceuticals
ALNY
|
43.3 | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
70.9 | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
58 | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
76.5 | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
104 | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
79 | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
249 | $ 4.07 | 2.21 % | $ 147 M | USA |
 |
Assembly Biosciences
ASMB
|
2.46 | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
AbbVie
ABBV
|
258 | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
4.13 | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
185 | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.87 | 0.53 % | $ 498 M |  Britain |
 |
Axon Enterprise
AXON
|
134 | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
105 | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
52.4 | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
13.8 | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Biogen
BIIB
|
50.7 | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
141 | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
52.5 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
5.06 | - | - | $ 401 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.24 | 0.89 % | $ 3.69 M | Israel |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
27.9 | $ 3.45 | 0.58 % | $ 286 M | USA |